Pfizer Corporation

Rinat Neuroscience Corporation

Allogene Therapeutics, Inc.

Javier Fernando Chaparro Riggers

Thomas John Van Blarcom

Arvind Rajpal

Tracy Chia-Chien Kuo

Pavel Strop

Edward Derrick Pascua

Yik Andy Yeung

Jaume Pons

Wei Chen

Weihsien Ho

Hong Liang

Leila Marie Boustany

Bruce Charles Gomes

Amy Shaw-Ru Chen

Yasmina Noubia Abdiche

Julie Jia Li Hawkins

Yuli Wang

Philippe Duchateau

Roman Galetto

Barbra Johnson Sasu

Thomas Charles Pertel

Cesar Adolfo Sommer

Bijan Andre Boldajipour

David L Shelton

Alexandre Juillerat

Julien Valton

Lidia Mosyak

Chia-Yang Lin

Wenwu Zhai

Edward Roland Lavallie

Laura Lin

Jeffrey Raymond Chabot

Xiayang Qiu

Sheng Ding

Davide Foletti

Regina Junhui Lin

Alison Jane Forgie

Andrea Rossi

Sara Iva Siebel

Kapil Mayawala

Jerome Thomas Mettetal, Ii

Jacob Eli Gunn Glanville

Lee Mary Beth Shaughnessy

Shih-Hsun Chen

Pawel Kamil Dominik

Shahram Salek-Ardakani

Jessica Lynn Stanfield

Reid Martin Renny Feldman

Ling Hon Matthew Chu

Andrew Ross Nager

Ivana Djuretic

Spencer Park

Samantha Lisa Bucktrout

Bevin Marie Brady Smith

Julie Jia Hawkins

The present invention provides inducible chimeric cytokine receptors responsive to a ligand, e.g., a small molecule or protein, uses of such receptors for improving the functional activities of genetically modified immune cells, such as T cells, comprising the inducible chimeric cytokine receptors, and compositions comprising such cells.

Inducible chimeric cytokine receptors

The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

Chimeric antigen receptors targeting B-cell maturation antigen

The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

Therapeutic antibodies and their uses

Antibodies that specifically bind to CD47 and antibodies that specifically bind to PD-L1 are provided, as well as CD47/PD-L1 bispecific antibodies. Also provided are uses of these antibodies, and related compositions and methods.

Antibodies specific for CD47, PD-L1, and uses thereof

The present invention provides antibodies that bind Glucocorticoid Induced Tumor necrosis factor Receptor family related protein (GITR) and methods of using same. The anti-GITR antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.

Anti-GITR antibodies and methods of use thereof

The present invention relates to bispecific antibodies that specific bind to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.

The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.

IL-15 variants and uses thereof

The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, or metabolic syndrome.

Anti-glucagon receptor antibodies and pharmaceutical compositions thereof

The present invention provides antagonizing antibodies that bind to growth hormone receptor (GHR). The invention further relates to therapeutic methods for use of these antibodies to reduce IGF-1 levels and/or for the treatment and/or prevention of diseases associated with excessive IGF-1, including treatment of acromegaly, gigantism, cancer, diabetic nephropathy, arthritis, and lung inflammation.

Human growth hormone receptor antagonist antibodies and methods of use thereof

The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

PCSK9 antagonists

Growing community of inventors

San Mateo, CA, United States of America

Javier Fernando Chaparro Riggers